Invited Commentary
Mar 12, 2012

Dabigatran: Do We Have Sufficient Data?Comment on “Dabigatran Association With Higher Risk of Acute Coronary Events”

Author Affiliations

Author Affiliations: The Jerusalem Institute of Aging Research, Department of Geriatrics and Rehabilitation, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel; and Hebrew University-Hadassah Medical School, Jerusalem, Israel.

Arch Intern Med. 2012;172(5):403-404. doi:10.1001/archinternmed.2011.1721

Dabigatran is certainly in the news at the moment. A PubMed search identified more than 500 publications—with 307 since the start of 2011 as well as a large direct-to-consumer advertising campaign—for this new direct thrombin inhibitor. Changes in anticoagulation therapy seem both likely and imminent.

The explosion of literature on dabigatran draws heavily from the 7 RCTs included in the meta-analysis of Uchino and Hernandez.1 Dabigatran is the primary contender among several to have reached the finish line of phase 3 trials largely unscathed and has gained approval both in the United States and Europe for prophylaxis of VTE and stroke in patients with nonvalvular AF.

First Page Preview View Large
First page PDF preview
First page PDF preview